Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals is a publicly traded biopharmaceutical company based in Pasadena, California. Arrowhead’s products in development act through RNA interference (RNAi) mechanisms of action.[2][3] The company focuses on treatments for Hepatitis B, the liver disease associated with alpha 1-antitrypsin deficiency (AATD) and cardiovascular disease.[2] The company has eight products in its pipeline, in various stages of development.[2]

ProductIndicationDevelopment phaseNotes
ARO-HBV[2]Hepatitis BIn Clinic Phase 1/2Partnered with Janssen
ARO-AAT[2]Alpha-1 Antirypsin DeficiencyIn Clinic Phase 1/2Orphan Drug Designation
ARO-APOC3[2]HypertriglyceridemiaPre-ClinicalOrphan Drug Designation
ARO-HIF2[2]Renal Cell CarcinomaPre-Clinical
ARO-ENaC[2]Cystic FibrosisPre-Clinical
ARO-ANG3[2]DyslipidemiaPre-ClinicalOrphan Drug Designation
AMG 890[2]Cardiovascular DiseaseIn Clinic Phase 1/2Partnered with Amgen
ARO-AMG1[2]Undisclosed CardiovascularPre-ClinicalPartnered with Amgen
Arrowhead Pharmaceuticals, Inc.
TypePublic
IndustryBiotechnology
HeadquartersPasadena, California, U.S.
Key people
Christopher Anzalone, Ph.D., president and chief executive officer

Bruce Given, M.D., chief operating officer

Ken Myszkowski, MBA, CPA, chief financial officer
Revenue $168.2 Million(2019)[1]
Number of employees
109
Websitearrowheadpharma.com

In 2015, the company substantially expanded its intellectual property holdings through complete acquisition of the full RNAi research and development portfolio, and assets from Novartis.[4][5]

In April 2016, it was announced that the former company name, Arrowhead Research Corporation, will be changed to Arrowhead Pharmaceuticals, Inc.[6]

In September 2016, Arrowhead entered into two collaboration and licensing agreements with Amgen. Under the deals, Amgen received a worldwide exclusive license to Arrowhead’s ARO-LPA RNAi program and an option to a worldwide exclusive license for ARO-AMG1, both for cardiovascular disease.[7]

On Oct. 31, 2018, Arrowhead Pharmaceuticals Inc. closed on a $3.7 Billion License and Collaboration Agreements with Janssen to develop and commercialize ARO-HBV. As part of the overall deal, Arrowhead entered into a research collaboration and option agreement with Janssen to potentially collaborate for up to three additional RNA interference (RNAi) therapeutics against new targets to be selected by Janssen.[8]

References
  1. https://www.macrotrends.net/stocks/charts/ARWR/arrowhead-pharmaceuticals/revenue
  2. "arwr-10q_20170331.htm". www.sec.gov. Retrieved 2017-05-17.
  3. "8-K". www.sec.gov. Retrieved 2017-05-17.
  4. "Arrowhead buys Novartis' RNAi portfolio". Reuters. 2017-03-05. Retrieved 2017-05-17.
  5. Staff (1 April 2015). "Novartis Sells RNAi R&D Portfolio to Arrowhead in $35M Agreement". News: Industry Watch. Genetic Engineering & Biotechnology News (Paper). 35 (7): 10.
  6. "Arrowhead Research Changes Name to Arrowhead Pharmaceuticals". www.businesswire.com. 2016-04-06. Retrieved 2020-04-06.
  7. "Amgen, Arrowhead team up on gene-therapies for heart disease". Reuters. 2017-09-29. Retrieved 2017-05-17.
  8. "Arrowhead Enters $3.7 Billion License and Collaboration". Marketwatch. 2018-10-04. Retrieved 2018-10-04.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.